PMID

Data

Article Title

Organization

Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.

Cellzome

A quantitative analysis of kinase inhibitor selectivity.

Ambit Biosciences

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

University of Oxford

In vitro and in silico studies on substrate recognition and acceptance of human PKMYT1, a Cdk1 inhibitory kinase.

Martin-Luther-University Halle-Wittenberg

Comprehensive analysis of kinase inhibitor selectivity.

Ambit Biosciences

Substituted N-aryl-6-pyrimidinones: a new class of potent, selective, and orally active p38 MAP kinase inhibitors.

Pfizer

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Ambit Biosciences

Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.

Repare Therapeutics

A small molecule-kinase interaction map for clinical kinase inhibitors.

Ambit Biosciences

Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1.

Martin-Luther-University Halle-Wittenberg

Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II.

Martin-Luther-University Halle-Wittenberg

Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.

Moffitt Cancer Center

Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.

University of Pittsburgh